02.05.2022 • NewsWuXi AppTecSingapore

Wuxi ATU Collaborates with Singapore’s BTI

WuXi Advanced Therapies (Wuxi ATU), US-based CDMO offshoot of WuXi AppTec, is joining up with Singapore’s Bioprocessing Technology Institute (BTI) to advance cell and gene therapy production in the Asia Pacific region.

Financial terms of the arrangement have not been disclosed.

The cooperation will focus on the Philadelphia, Pennsylvania-headquartered Wuxi arm’s Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology that improves adeno-associated virus (AAV) yields and particle quality. According to Wuxi, the platform produces significantly more AAV than plasmid-based manufacturing for cell and gene therapies.

Under the agreement, WuXi ATU will provide materials, equipment, funding and training to further develop and commercialize its technology. Singapore’s Bioprocessing Technology Institute will contribute its research expertise an facilities as well as affording access to its network of partners.

Koh Boon Tong, BTI’s executive director, called the collaboration “a significant step towards Singapore's goal to be an innovative biotherapeutics bioprocessing R&D hub.” 

Author: Dede Williams, Freelance Journalist

© Copyright 2020 WuXi AppTec. All Rights Reserved.
© Copyright 2020 WuXi AppTec. All Rights Reserved.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.